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ABSTRACT
Introduction: The primary aim of this analysis
was to explore whether glycemic control
(glycated hemoglobin [HbA1c] \7%) and the
incidence of hypoglycemia are different
between Chinese patients with type 2 diabetes
mellitus (T2DM) receiving oral
antihyperglycemic medication (OAM)-only or
insulin-only regimens.
Methods: Physicians in nine Chinese cities
completed surveys (Adelphi Real World
Diabetes Disease Specific Programme) from
October 2011 to March 2012. Key information
collected included patients’ demographic and
clinical characteristics, HbA1c levels, and
hypoglycemia incidence. Patients receiving
OAM-only (n = 1077) or insulin-only (n = 292)
regimens for C6 months who had most recent
HbA1c results available and measured within
3 months of survey completion were included.
The primary and secondary outcomes were
glycemic control and the incidence of
hypoglycemia. Primary (multivariate logistic
regression analysis with adjustment for
potential confounders) and sensitivity analyses
(propensity score matching method) were
performed.
Results: A higher proportion of patients in the
insulin-only group achieved glycemic control
than patients in the OAM-only group (41.8% vs
35.9%). Insulin-only treatment was associated
with significantly (P = 0.013) better glycemic
control than OAM-only treatment (odds ratio
[95% confidence interval]: 1.48 [1.09, 2.01]). A
higher proportion of patients in the insulin-
only group experienced hypoglycemia (overall)
than patients in the OAM-only group (33.3% vs
14.4%). Insulin-only treatment was associated
with significantly (P\0.001) increased overall
hypoglycemia compared with OAM-only
treatment (odds ratio [95% confidence
interval]: 2.38 [1.72, 3.29]). Sensitivity analysis
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results were consistent with the primary
analysis results.
Conclusions: The results of this analysis
provide important real-world information on
glycemic control and hypoglycemia in Chinese
patients with T2DM, which may be useful for
guiding evidenced-based management.
Notably, Chinese patients with T2DM
receiving OAM-only had poorer glycemic
control compared with those receiving insulin-
only therapy, although patients receiving OAM-
only were less likely to experience
hypoglycemic events.
Keywords: China; Insulin; Oral
antihyperglycemic medication; Type 2 diabetes
mellitus
INTRODUCTION
Diabetes is a significant and growing public
health issue in China. Indeed, recent estimates
suggest that there are over 100 million Chinese
adults with diabetes [1], nearly 500 million with
prediabetes [1], and that there will be more than
140 million Chinese adults with diabetes by
2035 [2]. Worryingly, a high proportion
(approximately 60%) of Chinese adults with
diabetes remains unaware of their condition
and those that are diagnosed tend to have
inadequate glycemic control [1]. Specifically,
only 41.1% of patients with type 2 diabetes
mellitus (T2DM) were found to have glycated
hemoglobin (HbA1c)\7.0% (\53 mmol/mol) in
the Diabcare China study [3]. In another (cross-
sectional hospital-based) study, 12.1% to 15.3%
of patients were found to have HbA1c \6.5%
(48 mmol/mol) [4]. Unsurprisingly, given that
many patients have poor glycemic control, the
morbidity and mortality associated with diabetes
in China is significant, as indicated by the high
proportion (over 50%) of patients who have
chronic diabetes-related complications [4] and
by the fact that diabetes is one of the major
causes of death [5]. Clearly, optimizing
treatment strategies will become increasingly
important as the population of Chinese
patients with diabetes continues to grow.
The current Chinese guidelines for the
prevention and treatment of T2DM [6] state
that lifestyle interventions are fundamental for
the treatment of T2DM. The current glycemic
target for the majority of Chinese patients with
T2DM is HbA1c \7%, with testing performed
every 3 months [6]. In cases where blood
glucose levels cannot be controlled by lifestyle
interventions only, the initiation of medical
treatment is recommended. To this end,
metformin is the recommended first-line
treatment, followed by second-line treatment
with a combination of two oral
antihyperglycemic medications (OAM), third-
line treatment with three OAMs or two OAMs
plus insulin (basal or premixed analog), and
fourth-line/intensive treatment with basal plus
mealtime insulin or a premixed analog.
Currently, the most common regimens used to
treat T2DM in China are OAM only, insulin
only, or OAM plus insulin [3, 7]. Identifying
means of improving glycemic control in
Chinese patients with T2DM on these
regimens is key to preventing diabetes-related
complications and morbidities. To date, there is
little information in the published literature on
differences in glycemic control between
Chinese patients with T2DM receiving insulin-
only and those receiving OAM-only treatment
regimens, or on how patient characteristics
affect glycemic control with these regimens.
The information that is available comes from
cross-sectional, prospective, or registry studies
(carried out in mainland China [7, 8] and Hong
Kong [9]) that did not perform adjustments for
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potentially confounding patient characteristics.
The availability of appropriately adjusted, real-
world data may help facilitate the development
of evidence-based treatment strategies for
improving glycemic control in Chinese
patients with T2DM.
The primary aim of this analysis was to
explore whether glycemic control (HbA1c\7%)
and the incidence of hypoglycemia are different
between Chinese patients with T2DM receiving
OAM-only and those receiving insulin-only
treatment regimens after adjusting for key
patient characteristics. The secondary aim of
this analysis was to explore which factors were
associated with glycemic control and the
incidence of hypoglycemia, respectively. We
did not include patients receiving concomitant
OAM and insulin treatment regimens in our
analyses because regimens for this combination
can be highly variable between patients,
making it difficult to identify the distinct




The Adelphi Real World Disease Specific
Programme (DSP) is a large, cross-sectional
survey of physicians and patients in a real-
world clinical setting, which uses representative
sampling of treated adult patients for
quantification of national disease burden and
assessment of treatment patterns and outcomes
[10]. The DSP provides a holistic picture of a
disease and treatment of that disease; the full
methodology of the DSP has been published
previously [11, 12].
The Diabetes DSP was carried out in China
from October 2011 to March 2012 in
accordance with European Pharmaceutical
Marketing Research Association guidelines.
Physicians were reimbursed for their
participation by local fieldwork partners at
fair-market rates. DSP fieldwork teams adhered
to national data collection regulations.
Survey Distribution
Physicians treating patients with T2DM at general
hospitals in Beijing, Shanghai, Guangzhou,
Hangzhou, Nanjing, Chengdu, Wuhan,
Shenyang, and Xi’an were invited to participate.
These physicianswere identified by local fieldwork
teams from public lists according to predefined
selection criteria. Specifically, physicians who had
qualified between 1973 and 2009, were actively
involved in diabetes management, and saw 25 or
more (internalmedicine physicians) or 50 ormore
(diabetologists and endocrinologists) patientswith
diabetes in a typical week were eligible to
participate. Those who agreed to participate were
sent physician-report forms [12] for completion.
Completed surveys were collected by local
fieldwork teams and returned to Adelphi Real
World.
Survey Design
The survey was designed by Adelphi Real World
in consultation with their local fieldwork
partner in China. The physician-report form
was self-administered, used clinical
terminology, maintained patients’ anonymity,
and was confidential. All questions were
originally written in English and translated
into Simplified Chinese by the fieldwork
partner. The translated version of the
physician-report form was linguistically
validated by a second independent native
Chinese translator agency.
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Physician-Report Form
The physician-report form collected
information on patients’ demographics,
clinical characteristics, clinical management
and outcomes (including glycemic control and
hypoglycemia [chart review was necessary]),
diabetes medication use and history, and
physician rationale for treatment choices. The
physician-report form also collected
information on compliance with diabetes
medication (rated by physicians as not at all,
poor, fair, or full), physical activity (recorded by
physicians as not at all, fairly, very, or extremely
active), and lifestyle changes (recorded by
physicians as no changes, some changes, many
changes, or totally changed).
To answer some of the more clinical and in-
depth questions, the majority of physicians
would have had to refer to medical records, in
which patients’ medical histories, including
medication history from different hospitals or
physicians would be accurately recorded.
Participating physicians were those most
commonly responsible for treating patients
with T2DM in China, namely internal
medicine physicians, diabetologists, or
endocrinologists. Internal medicine physicians
were asked to complete physician-report forms
for the next nine consecutive patients receiving
non-insulin medication with or without insulin
regimens and the following two forms for
consecutive patients receiving insulin-only
regimens. Diabetologists and endocrinologists
were asked to complete physician-report forms
for the next eight consecutive patients receiving
non-insulin medication with or without insulin
regimens and the following two forms for
consecutive patients receiving insulin-only
regimens. The physician-report form quotas
per physician for each regimen were based on
the prevalence of T2DM in China and the
duration of the survey.
Analysis Population
The population for this analysis included
patients with T2DM receiving OAM-only or
insulin-only treatment regimens for at least
6 months who had most recent HbA1c results
available and measured within 3 months of
survey completion. Patients were required to
be on these regimens for at least 6 months to
ensure that the HbA1c result obtained reflected
average plasma glucose concentrations during a
period of consistent treatment.
Outcomes (OAM-Only vs Insulin-Only)
The primary outcome was glycemic control,
defined as HbA1c \7% and determined using
the most recent HbA1c test result (assessed at
the treating hospital) within 3 months of the
survey date.
The secondary outcome was hypoglycemia,
defined as any hypoglycemic episode that
occurred on the treatment regimen.
Hypoglycemic episodes were solicited by
physicians from patients and were categorized
by incidence as overall, severe, and nocturnal.
Patients were provided with practical
definitions of hypoglycemia. Mild
hypoglycemic episodes were those that were
treated by the patient by eating fruit, fruit juice,
sweets, etc. Severe hypoglycemic episodes were
those where the patient required third party or
medical assistance. Hypoglycemia was not
confirmed by blood glucose measurement.
As an exploratory, composite outcome, the
proportion of patients attaining the HbA1c target
\7% without hypoglycemia was also determined.
Statistical Analysis
The patients’ characteristics were compared
between the OAM-only and insulin-only
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groups by Wilcoxon rank sum test for
continuous variables or Fisher’s exact test for
categorical variables.
The primary analysis of the primary,
secondary, and composite outcomes comprised
multivariate logistic regression analysis, with
adjustments for age, duration since diagnosis of
diabetes, education (less than high school vs. at
least high school), dietary adaption (no/some
changes vs. many changes/totally changed),
physical activity (not at all/fairly active vs.
very/extremely active), body mass index (BMI),
current employment/student status (yes vs. no),
treatment compliance (not at all/poorly vs.
fairly/fully compliant), and self-monitoring of
blood glucose concentrations (yes vs. no).
Sensitivity analysis of the primary and
secondary outcomes was carried out using the
propensity score (PS) matching method, which
generated matched pairs to balance the
patients’ characteristics between the two
groups. All unbalanced characteristics were
included in the PS model. A 1:1 (OAM-only:
insulin-only) greedy matching algorithm
without replacement and with a specified
caliper distance (\0.2 standard deviations of
the logit of the PS) were used to identify the
matched pairs. The balance of the matched
treatment groups was determined by assessing
the standardized difference, which compares
the difference in means in units of the pooled
standard deviation. A standardized difference
\0.1 was taken to indicate a negligible
difference in the mean or prevalence of a
covariate between treatment groups [13]. After
matching, a generalized estimating equation
(GEE) model with binomial distribution and
logit link function was used to compare
outcomes between the treatment groups.
A two-sided significance level of 0.05 was
used for all analyses, which were carried out
using SAS version 9.2 (SAS Institute Inc., Cary,
NC, USA). Adjustments for multiplicity were
not made due to the exploratory nature of the
analyses.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Analysis Population
A total of 200 physicians completed 2060
physician-report forms. Of these physician-
report forms, 599 were excluded from the
analyses for the following reasons (note: some
forms may have had multiple reasons for
exclusions): HbA1c not tested within
3 months, n = 360; received medication for
\6 months, n = 262; and time since diagnosis
not available, n = 39. Of the remaining 1461
physician-report forms, 1077 were for patients
receiving OAM-only regimens, 292 were for
patients receiving insulin-only regimens, and
92 were for patients receiving OAM and insulin
regimens. The patients receiving OAM and
insulin regimens were excluded, leaving 1369
patients on OAM-only or insulin-only regimens
for inclusion in the analysis population.
Patient Characteristics
There were several significant differences in
patient characteristics between the OAM-only
and insulin-only groups (Table 1). Specifically,
patients in the OAM-only group were younger,
more recently diagnosed with T2DM, more
frequently employed/students, more physically
Diabetes Ther (2015) 6:197–211 201









Mean (SD) 56.2 (10.8) 57.9 (11.0) 56.5 (10.8)
Median (Q1, Q3) 56 (49, 63) 57 (50, 65) 56 (49, 64) 0.029
Male sex, n (%) 505 (46.9) 128 (43.8) 633 (46.2) 0.390
BMI (kg/m2)
Mean (SD)b 24.4 (3.1) 24.1 (2.7) 24.3 (3.0)
Median (Q1, Q3) 24.1 (22.0, 26.1) 23.7 (22.2, 26.0) 24.0 (22.1, 26.1) 0.338
Time since diagnosis of T2DM (years)
Mean (SD) 3.2 (3.0) 4.3 (4.5) 3.4 (3.4)
Median (Q1, Q3) 2 (1, 4) 3 (2, 5) 2 (1, 4) \0.001
Education level, n (%)c 0.204
Less than high school 253 (24.8) 75 (28.7) 328 (25.6)
At least high school 766 (75.2) 186 (71.3) 952 (74.4)
Currently employed/student, n (%)d 441 (41.0) 95 (32.6) 536 (39.2) 0.010
Current smoker, n (%)e 150 (14.4) 34 (11.9) 184 (13.9) 0.333
Treatment compliantf, n (%)g 0.327
Not at all/poorly 183 (17.1) 42 (14.5) 225 (16.6)
Fairly/fully 887 (82.9) 247 (85.5) 1134 (83.4)
Dietary adaptation, n (%)h 0.891
No/some changes 397 (36.9) 106 (36.3) 503 (36.8)
Many changes/totally changed 679 (63.1) 186 (63.7) 865 (63.2)
Physically active, n (%)i 0.022
Not at all/fairly 138 (12.8) 53 (18.2) 191 (14.0)
Very/extremely 938 (87.2) 238 (81.8) 1176 (86.0)
Self-monitored blood glucose (yes), n (%)j 403 (41.0) 198 (70.7) 601 (47.5) \0.001
BMI body mass index, OAM oral antihyperglycemic medication, Q1 ﬁrst quartile, Q3 third quartile, SD standard deviation,
T2DM type 2 diabetes mellitus
a Continuous variables were compared between the OAM-only and insulin-only groups by Wilcoxon rank sum test.
Categorical variables were compared between these groups by Fisher’s exact test
b Missing data (n): OAM = 4, insulin = 2
c Missing data (n): OAM = 58, insulin = 31
d Missing data (n): OAM = 1, insulin = 1
e Missing data (n): OAM = 34, insulin = 7
f Rated by physicians as not at all, poorly, fairly, or fully compliant
g Missing data (n): OAM = 7, insulin = 3
h Missing data (n): OAM = 1
i Missing data (n): OAM = 1, insulin = 1
j Missing data (n): OAM = 93, insulin = 12
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active, and less commonly self-monitored blood
glucose concentrations than patients in the
insulin-only group (all P\0.05). A high
proportion ([80%) of patients in both groups
were fairly or fully compliant with treatment
according to physicians’ ratings.
Using the PS matching method to balance
the characteristics of two treatment groups, a
total of 474 patients (237 per treatment group)
were successfully matched. All patient
characteristics were well balanced (all P[0.2;
standardized difference \0.1) (Table 2; Fig. 1).
Thus, matched patients from the 2 treatment




Without any adjustment, a higher proportion of
patients in the insulin-only group achieved
glycemic control (HbA1c \7%) than patients
in the OAM-only group (41.8% [122/292] vs
35.9% [387/1077]). After adjusting for potential
confounding factors, insulin-only treatment
was associated with significantly better
glycemic control (odds ratio [OR] [95%
confidence interval {CI}]): 1.48 [1.09, 2.01],
P = 0.013) than OAM-only treatment (Fig. 2).
Other factors that were associated with
significantly better glycemic control included a
shorter time since diagnosis of T2DM (OR [95%
CI]: 0.87 [0.83, 0.92], P\0.001), dietary
adaptation involving many changes or total
changes (OR [95% CI]: 2.33 [1.78, 3.04],
P\0.001), physical activity defined as very/
extremely active (OR [95% CI]: 2.16 [1.42, 3.29],
P\0.001), a BMI of 24.0–27.9 kg/m2 (OR [95%
CI]: 1.44 [1.11, 1.86], P = 0.006), and treatment
compliance (OR [95% CI]: 3.26 [2.14, 4.96],
P\0.001).
Sensitivity Analysis
A total of 237 paired patients were included in
the sensitivity analysis. The results of the
sensitivity analysis for glycemic control were
consistent with the results of the primary
analysis. A higher proportion of patients in
the insulin-only group achieved glycemic
control (HbA1c \7%) than patients in the
OAM-only group (47.3% [112/237] vs 38.0%
[90/237]). The GEE model showed that insulin-
only treatment was associated with significantly
better glycemic control than OAM-only




Without any adjustment, a higher proportion of
patients in the insulin-only group reported
experiencing hypoglycemia (overall), severe
hypoglycemia, and nocturnal hypoglycemia
than patients in the OAM-only group (33.3%
[97/291] vs 14.4% [155/1074], 8.6% [25/291] vs
1.6% [17/1074], and 16.2% [47/291] vs 7.9% [85/
1074], respectively). After adjusting for potential
confounding factors, insulin-only treatment was
associated with significantly (OR [95% CI]: 2.38
[1.72, 3.29], P\0.001) increased overall
hypoglycemia compared with OAM-only
treatment (Fig. 3). Other factors that were
significantly (all P\0.01) associated with
overall hypoglycemia included a longer time
since diagnosis of T2DM, dietary adaptation
involving many changes or total changes, and
self-monitoring of blood glucose concentrations.
Sensitivity Analysis
The results of the sensitivity analysis for
hypoglycemia were consistent with the results
of the primary analysis. A higher proportion of
patients in the insulin-only group reported
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Mean (SD) 56.9 (11.6) 57.3 (10.6) 57.1 (11.1)
Median (Q1, Q3) 56 (49, 65) 57 (50, 64) 57 (50, 64) 0.522
Male sex, n (%) 110 (46.4) 104 (43.9) 214 (45.1) 0.645
BMI (kg/m2)
Mean (SD) 24.2 (3.0) 24.3 (2.7) 24.2 (2.8)
Median (Q1, Q3) 23.8 (21.9, 26.0) 23.9 (22.5, 26.2) 23.9 (22.2, 26.1) 0.258
Time since diagnosis of T2DM (years)
Mean (SD) 3.8 (3.7) 3.8 (3.5) 3.8 (3.6)
Median (Q1, Q3) 3 (2, 5) 2 (2, 5) 3 (2, 5) 0.787
Education level, n (%)b 0.742
Less than high school 55 (25.0) 57 (26.8) 112 (25.9)
At least high school 165 (75.0) 156 (73.2) 321 (74.1)
Currently employed/student, n (%) 92 (38.8) 81 (34.2) 173 (36.5) 0.340
Current smoker, n (%)c 25 (11.1) 27 (11.6) 52 (11.4) 0.884
Treatment compliantd, n (%) 1.000
Not at all/poorly 30 (12.7) 30 (12.7) 60 (12.7)
Fairly/fully 207 (87.3) 207 (87.3) 414 (87.3)
Dietary adaptation, n (%) 0.562
No/some changes 85 (35.9) 78 (32.9) 163 (34.4)
Many changes/totally changed 152 (64.1) 159 (67.1) 311 (65.6)
Physically active, n (%) 0.804
Not at all/fairly 40 (16.9) 37 (15.6) 77 (16.2)
Very/extremely 197 (83.1) 200 (84.4) 397 (83.8)
Self-monitored blood glucose (yes), n (%) 168 (70.9) 169 (71.3) 337 (71.1) 1.000
BMI body mass index, OAM oral antihyperglycemic medication, Q1 ﬁrst quartile, Q3 third quartile, SD standard deviation,
T2DM type 2 diabetes mellitus
a Continuous variables were compared between the OAM-only and insulin-only groups by Wilcoxon rank sum test.
Categorical variables were compared between these groups by Fisher’s exact test
b Missing data (n): OAM = 17, insulin = 24
c Missing data (n): OAM = 12, insulin = 5
d Rated by physicians as not at all, poorly, fairly, or fully compliant
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experiencing hypoglycemia (overall), severe
hypoglycemia, and nocturnal hypoglycemia
than patients in the OAM-only group (36.0%
[85/236] vs 16.5% [39/237], 8.9% [21/236] vs
1.3% [3/237], and 18.6% [44/236] vs 8.4% [20/
237], respectively). The GEE model showed that
insulin-only treatment was associated with
significantly increased overall hypoglycemia
compared with OAM-only treatment (OR [95%
CI]: 2.86 [1.89, 4.34], P\0.001).
Glycemic Control Without Hypoglycemia
The proportion of patients attaining HbA1c
\7% without hypoglycemia was similar in both
groups (29.98% in the OAM-only group vs
26.46% in the insulin-only group).
Both univariate and multivariate analyses
revealed that there was no association between
the type of treatment and the composite outcome,
HbA1c\7% without hypoglycemia (P[0.24). In
contrast, HbA1c\7% without hypoglycemia was
significantly associated with a shorter time since
diagnosis of T2DM (OR [95%CI]: 0.86 [0.81, 0.92],
P\0.001), many changes/totally changed diet
(OR [95% CI]: 1.96 [1.47, 2.61], P\0.001), very
active/extremely active physical activity (OR [95%
CI]: 1.72 [1.09, 2.71], P= 0.020), and full/fair
treatment compliance (OR [95% CI]: 3.09 [1.94,
4.90], P\0.001).
DISCUSSION
This is the first analysis to explore whether
glycemic control is different between Chinese
patients with T2DM receiving OAM-only and
those receiving insulin-only treatment
regimens after adjusting for key patient
Fig. 1 Standardized differences for patient characteristics
before and after propensity score matching. A standardized
difference\0.1 was taken to indicate a negligible difference
in the mean or prevalence of a covariate between treatment
groups [13]. All characteristics were well balanced
(standardized difference \0.1) after propensity score
matching. BMI body mass index, FBG fasting blood
glucose, HbA1c glycated hemoglobin, T2DM type 2
diabetes mellitus
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characteristics. The main findings of our
analysis are that, in patients with similar core
clinical and demographic characteristics,
insulin-only treatment was associated with
significantly better glycemic control (HbA1c
\7%) than OAM-only treatment and
significantly increased overall hypoglycemia
compared with OAM-only treatment. We also
identified several other distinct factors
associated with better glycemic control,
including shorter time since diagnosis of
T2DM, dietary adaptation, physical activity,
BMI, and treatment compliance. Several
factors were also found to be associated with
hypoglycemia, including insulin-only
treatment, longer time since diagnosis of
T2DM, dietary adaptation, and self-monitoring
of blood glucose. This analysis provides
important real-world information on factors
affecting glycemic control and hypoglycemia
in Chinese patients with T2DM, which may be
useful for guiding evidenced-based
management strategies.
Consistent with findings from other studies
[3, 4, 14–17], we found that a relatively low
proportion of Chinese patients with T2DM had
adequate glycemic control (HbA1c \7%).
Importantly, however, we also found that
insulin-only treatment regimens may provide
better glycemic control than OAM-only
treatment regimens in patients with similar
core clinical and demographic characteristics.
Previous cross-sectional, prospective, registry, or
survey studies carried out in China (mainland
[7, 8] and Hong Kong [9]) and elsewhere [18, 19]
comparing glycemic control between patients
Fig. 2 Multivariate analysis of variables associated with
glycemic control (glycated hemoglobin \7%) in Chinese
patients with type 2 diabetes mellitus receiving oral
antihyperglycemic medication-only or insulin-only
treatment regimens. BMI body mass index, CI conﬁdence
interval, OAM oral antihyperglycemic medication, OR odds
ratio, T2DM type 2 diabetes mellitus. aOverall P value for
BMI (type 3 analysis of effects)
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receiving insulin-only and OAM-only treatment
regimens have not made these comparisons
after adjustment for potentially confounding
patient characteristics. In contrast to the
present analysis, these previous studies found
that patients receiving OAM-only treatment
regimens had better levels of glycemic control
than patients receiving insulin-only treatment
regimens. Our findings therefore highlight the
importance of adjusting for patient
characteristics when evaluating glycemic
control. Differences in patient cohort
characteristics, in particular disease duration
(generally shorter in our analysis), between our
analysis and previous studies [7–9, 18, 19] may
also have contributed to the different findings
regarding glycemic control.
We found that a number of other factors
were associated with glycemic control,
including modifiable factors such as patients’
dietary adaption, physical activity level, BMI,
and treatment compliance, as well as the non-
modifiable factor, duration of disease. These are
all well-established factors known to be
important in the management of T2DM/
glycemic control [6, 14, 20–23]. A high level of
treatment compliance, more pronounced
dietary adaptation, and increased physical
activity had the strongest associations with
better glycemic control. Our finding regarding
treatment compliance is noteworthy given that
a high proportion ([80%) of patients were
considered to be fairly or fully compliant by
their physicians. Therefore, it is clear that
Fig. 3 Multivariate analysis of variables associated with
hypoglycemia in Chinese patients with type 2 diabetes
mellitus receiving oral antihyperglycemic medication-only
or insulin-only treatment regimens. BMI body mass index,
CI conﬁdence interval, OAM oral antihyperglycemic med-
ication, OR odds ratio, T2DM type 2 diabetes mellitus.
aOverall P value for BMI (type 3 analysis of effects)
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Chinese physicians and healthcare providers
managing patients with T2DM have an
important role to play in educating and
encouraging patients to ameliorate these
modifiable factors in the management of their
condition.
The effective treatment of diabetes is a
delicate balance between good glycemic
control and managing the risk of
hypoglycemia, an established risk of treatment
with insulin [23, 24]. Hence, our finding that
insulin-only treatment was associated with an
increased incidence of hypoglycemia in
Chinese patients with T2DM compared with
OAM-only treatment is unsurprising. There are
a number of key modifiable factors affecting this
balance, including the type of medication,
medication dose, glycemic control target, diet,
exercise, non-diabetic drug/alcohol use, and
blood glucose monitoring [25–27]. Patient-
centric individualization of treatment is an
important consideration [27], emphasized by
the Chinese Diabetes Society, the American
Diabetes Association, and the European
Association for the Study of Diabetes [28, 29].
Interestingly, we found that patients who made
many changes or totally changed their diet had
increased hypoglycemia compared with those
who made no or some changes to their diet.
This finding suggests many Chinese patients
with T2DM receiving insulin-only or OAM-only
treatment regimens who change their diet may
not understand/be aware of the importance of
the relationship between diet, diabetes
medication, and blood glucose concentrations.
Therefore, more comprehensive patient
education on diet/meal planning, including
appropriate titration of insulin dosing, may be
necessary. Indeed, several previous studies have
demonstrated the importance of education for
improving glycemic control in Chinese patients
with T2DM, particularly among those who have
lower incomes and/or are less educated [20, 30].
We also found that self-blood glucose
measurement was associated with an increased
incidence of hypoglycemia. Our analysis does
not allow us to draw any conclusion regarding
the direction of this relationship; hence, we
suggest that patients who more commonly
experienced hypoglycemia may have been
more likely to measure their blood glucose
concentrations, indicating the possibility of
ascertainment bias in the sample. Indeed, the
Chinese Diabetes Society recommends that
patients with T2DM should measure their
blood glucose concentrations when symptoms
of hypoglycemia occur [29].
Composite outcomes have been used to assess
overall disease control, including in the context
of T2DM [31]. In the present analysis, we did not
find any association between treatment and the
composite outcome, glycemic control (HbA1c
\7%) without hypoglycemia. However, in
agreement with the analysis of glycemic
control, glycemic control without
hypoglycemia was associated with several
modifiable factors, including patients’ dietary
adaptation, physical activity level, and treatment
compliance, as well as the non-modifiable factor,
duration of disease. The associations between
glycemic control without hypoglycemia and
these modifiable factors again emphasize the
importance of patients being made aware that
aspects of their behavior/lifestyle can affect
treatment outcomes.
This analysis has several noteworthy
strengths, including the use of real-world data
and the strong agreement in the results of the
primary and sensitivity analyses. Limitations
include that data were obtained from patients
being treated in a selected number of medium
or large cities (hence, the results may not be
applicable to the larger [non-urban] Chinese
population); that several factors (e.g.,
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hypoglycemia and treatment compliance) were
not objectively assessed; and that the cross-
sectional design does not allow for assessment
of the effect of T2DM treatment regimens or
compliance on longitudinal glycemic control at
the time of the survey. Although the
assessments of hypoglycemia and treatment
compliance were not objective, it must be
emphasized that the means of assessment
described are widely used in real-world clinical
practice in China and therefore drive treatment
decisions.
CONCLUSION
In summary, the main finding of our analysis is
that insulin-only treatment was associated with
better glycemic control than OAM-only
treatment in Chinese patients with T2DM.
This is an important finding given that
glycemic control is essential for preventing
diabetes-related complications and that many
patients with T2DM in China have inadequate
glycemic control. Prospective studies are needed
to further explore this finding and determine,
considering the increased risk of hypoglycemia,
whether certain subsets of Chinese patients
with T2DM may benefit from insulin-only
treatment rather than OAM-only treatment.
Studies are also needed to determine which
potentially modifiable factors targeted for
specific interventions may improve outcomes
for patients on these regimens.
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